PHIO PHARMACEUTICALS CORP
PHIONASDAQTrading Snapshot
- Day Range
- $1.01 – $1.04
- 52-Week Range
- $0.81 – $4.19
- Volume
- $2.48B
- Avg Volume
- $2.89B
- Shares Outstanding
- 11.6M
- Next Earnings
- Dec 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $571,828
- P/E Ratio
- -0.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.11
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1375.3%
Why Investors Own PHIO
- ✓High-growth profile — revenue up +10.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PHIO PHARMACEUTICALS CORP
PHIO
StockOtter · stockotter.spaceAbout PHIO PHARMACEUTICALS CORP
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clin
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinica
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements King of Prussia, Pe
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company